Table 2

Derivation by TaqMan PCR erbB-2/p16 from serum and from tumors in individuals with esophageal cancer and abnormal serum values

Sample no.DiagnosisaNo. of casesTaqMan PCR
SerumTumor
Nonmalignant esophageal lesion50.8–1.5 (1.1)b
 77Achalasia, megaesophagus0.8
 52Stricture1.0
 41Staple exclusion1.1
 58Hiatal hernia1.3
 73Epiphrenic diverticulum1.5
Barrett’s metaplasia of esophagus50.8–1.7 (1.2)b
 45Barrett’s, severe esophagitis0.8
 64Barrett’s0.9
 50Barrett’s with dysplasia1.3
 67Barrett’s with high-grade dysplasia1.6
 74Barrett’s with high-grade dysplasia1.7
Malignancy of esophagus (normal serum), pretreated with anticancer therapy110.9–1.7c0.4–1.8
 55III/adeno/cardia0.90.4
 53III/squamous cell/lower1.0
 70III/adeno/cardia1.10.6
 66IIB/adeno/middle1.11.4
 71IIA/adeno/lower1.11.4
 44IIA/adeno/lower1.31.8
 48I/adeno/lower1.30.9
 54I/adeno/lower1.41.5
 59III/adeno/cardia1.41.1
 78IIB/adeno/lower1.7
 79III/adeno/lower1.70.4
Malignancy of esophagus (normal serum); not pretreated140.7–1.6c0.4–34.3c
 80IIB/adenol/cardia0.734.3f
 47IIA/adeno/cardia0.91.8
 46I/adeno/lower1.0
 69I/adeno/cardia1.01.0
 42III/adeno/lower1.10.7
 49IIA/squamous cel/lower1.11.4
 56IVA/adeno/cardia1.1
 61IIA/adeno/cardia1.21.0
 63I/adeno/lower1.2
 51III/adeno/lower1.41.6
 65IIB/adeno/cardia1.40.5
 43IVA/adeno/cardia1.50.8
 75III/adeno/lower1.60.4
 68I/adeno/lower1.6
Malignancy of esophagus (abnormal serum), not pretreated52.0–3.8c2.5–8.9c
 57III/squamous cell/middle2.02.5
 60I/adeno/cardia2.27.9
 72III/adeno/lower2.58.9
 62IIA/adeno/lower3.73.1
 76IVA/adeno/lower3.8NAd
  • a Slashes represent stage/type/anatomic location. adeno, adenocarcinoma.

  • b Values represent ranges (means).

  • c Not including the tumor with a TaqMan PCR value of 34.3.

  • d NA, not available.